Diagnostic Center | December 13, 2022
Moderna and Merck announce personalized mRNA cancer vaccine
Results are the first demonstration of efficacy for an investigational mRNA cancer treatment in a randomized clinical trial
Results are the first demonstration of efficacy for an investigational mRNA cancer treatment in a randomized clinical trial
Presentations include new data on investigational medicines – favezelimab (MK-4280), zilovertamab vedotin (MK-2140) and nemtabrutinib – as well as KEYTRUDA (pembrolizumab) in multiple blood cancers
In first-line metastatic NSCLC, KEYTRUDA-based regimens have now shown a five-year survival benefit in four trials
Longer-term survival results underscoring role of KEYTRUDA (pembrolizumab) in multiple cancer types, including advanced nonsquamous non-small cell lung cancer (KEYNOTE-189)
Immune-mediated events and infusion reactions were higher with KEYTRUDA (38% vs 9%, respectively).
Globally, cervical cancer is the fourth most common cancer among women, with approximately 30,447 new cases diagnosed in Europe in 2020
At the interim analysis, the combination of Keytruda and Lynparza did not demonstrate a benefit in overall survival (OS), one of the study’s dual primary endpoints, compared to the control arm of either abiraterone acetate or enzalutamide
Guardant360 CDx is a comprehensive genomic profiling test that utilizes blood samples from patients with advanced solid cancers
_256_384.jpg)
The council has also reduced the GST to 5 per cent on a few more Covid-19 medicines
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)
